Emicizumab ( DrugBank: Emicizumab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
288自己免疫性後天性凝固因子欠乏症7

288. 自己免疫性後天性凝固因子欠乏症


臨床試験数 : 206 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05500807
(ClinicalTrials.gov)
November 1, 202212/8/2022Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia AEmicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia AVon Willebrand Disease, Type 3;Concomitant VWD and HemophiliaDrug: EmicizumabBleeding and Clotting Disorders Institute Peoria, IllinoisGenentech, Inc.Recruiting2 Years90 YearsAll40Phase 1United States
2NCT05345197
(ClinicalTrials.gov)
August 31, 202218/4/2022Emicizumab in Patients With Acquired Hemophilia AEmicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical TrialAcquired Hemophilia ADrug: emicizumabUniversity of WashingtonGenentech, Inc.Recruiting18 YearsN/AAll51Phase 2United States
3NCT04567511
(ClinicalTrials.gov)
September 1, 202129/7/2020Hemlibra in Mild Hemophilia AProspective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia AFactor VIII Deficiency, CongenitalDrug: EmicizumabIndiana Hemophilia &Thrombosis Center, Inc.Genentech, Inc.Recruiting5 Years45 YearsMale40Phase 4United States
4EUCTR2019-004430-42-AT
(EUCTR)
22/06/202122/04/2021Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history.Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial Acquired Hemophilia A (AHA)
MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851
MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Hemlibra®
INN or Proposed INN: Emicizumab
Other descriptive name: RO5534262 EMICIZUMAB
GWT-TUD GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
47Phase 2Austria;Germany
5NCT04188639
(ClinicalTrials.gov)
March 23, 20214/12/2019Emicizumab in Acquired Hemophilia AEmicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical TrialHemophilia A, AcquiredDrug: Emicizumab InjectionGWT-TUD GmbHHoffmann-La Roche;Hannover Medical SchoolCompleted18 YearsN/AAll47Phase 2Austria;Germany
6EUCTR2019-004430-42-DE
(EUCTR)
25/01/202120/11/2020Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history.Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial Acquired Hemophilia A (AHA)
MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851
MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Hemlibra®
INN or Proposed INN: Emicizumab
Other descriptive name: RO5534262 EMICIZUMAB
GWT-TUD GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
47Phase 2Austria;Germany
7JPRN-JapicCTI-205151
15/6/202007/02/2020PHASE III STUDY OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AGEHA)A MULTICENTER, OPEN-LABEL, NON-RANDOMIZED, PHASE III STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A Acquired hemophilia AIntervention name : emicizumab (ACE910, RO5534262)
INN of the intervention : emicizumab
Dosage And administration of the intervention : Emicizumab will be administered subcutaneously once weekly.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Chugai Pharmaceutical Co., Ltd.NULLcomplete18BOTH11Phase 3Japan